Member Info for SS17

This is based on latest annual reports published 6th May 2020

It’s a well diversified with massive potential, each of its portfolio co could be worth over £100 Mcap , with conservative estimate we are looking x7 at minimum around a £1! This will be a huge tek co with its innovative idea and products!

Couldn’t resist but topping up at 12.15 now. Spread is quite high although when I bought at that it was showing 11.p !
Guident 100%
Belluscura 18.9%
Salarius 91%
Lucyd 100

Thanks Bhargav for sharing your views. I have been holding it for long time started buying at 15p. I’m still positive and it’s worth waiting to see whether Newmont make it a success! I was in GGP as well but when Newmont pulled out I closed my position with a decent profit. I had around a million shares , wish I didn’t sell it At that time as now it’s over 12p and my average was only 1p! I’m hoping Omi could be perform similarly or better x10 ! Lot of if and but .. that’s how Market is especially gold and oil mining Co ! Worth the risk considering the reward! DYoR

When oil price goes above $50, RKH will be re-rated according to Se lion proportionate NPV; looking x10 of current SP. Just topped up at 8.45. PMO seems doing well and hope they will give this project priory to keep . Patience will be rewarded! dyor

Don't understand why SP is below 5p when Newmont subscribed for share it was at 5p and at that time gold price was around $1200, now over $1700. What fundamentally changed since then? unless any material change SP should be much higher given gold price up significantly. Any one can shed some light on it who has better knowledge on IMI reserve and in the gold mining industry?

Below statements summarise IMM potential... I think it's a smarter way to raise cash without diluting existing s/h value, also adding specialist investor which increase IMM profile and access to institutional investors: for that reason I have just topped up at 15.85! short term it may fluctuate and it has future?Dyor
"This is the first significant investment from specialist US healthcare funds and illustrates the attention we are now receiving from knowledgeable global investors. It particularly exemplifies the strengthened investment thesis of ImmuPharma, as we continue to strengthen and progress our recently expanded development pipeline to value inflexion points, including Lupuzor"

Jpm bullish on oil ... by 2025 $190! Crazy ... imagine what would be hurricane sp?

https://seekingalpha.com/article/4352461-190-oil-j-p-morgan-thinks-possible

What value should be for this partnership itself ? With current Macap around £80m, it looks attractive investment! DYoR
“Open Orphan will provide a new UK Covid-19 antibody test by partnering with Swiss pharma firm Quotient (NASDAQ:QTNT). Quotient has an antibody microarray system called MosaiQ, a specialist tool used to detect thousands of DNA expressions at the same time.
Quotient has entered into an exclusive contract with Open Orphan subsidiary hVIVO to support COVID-19 antibody testing in the UK.”

MosaiQ is the world’s first fully automated testing solution that allows for rapid diagnostics on blood, serum, or plasma samples obtained through venous blood draw. The high-throughput system consolidates multiple analyzers onto one microarray, a miniaturized biochip, creating cross-functional value for labs. The MosaiQ instrument is CE marked and the microarray manufacturing facility is ISO 13485 certified.

Fundamental is strong here, couldn't resist but topping up at 11.75 now! It's not just a covid play, this co has more to offer and could be take over target. Worth taking some risk, dyor

it disappointing to see you out of the Hurr, you spent so much time doing research and sharing useful info with us. You will be missed and I think you may have made poor decision by selling at this stage though. We will see in next few days, SP will stabilise and gradually going up as happened with PMO and Tullow.. all bad news is out, but Hurr still has massive reserve in the ground, surely big Oil giant like Sehll or BP would like to have have them in their portfolio

Some times changes is good, Dr T did his best, It's time for a change! As shareholder we would like our Hurr value to appreciate, I think now the co is going to move towards the right direction. It's depressing to see SP below 20p, it has to go up and new management will make sure if starts rolling. Looks at PMO and tullow, how the SP moving faster, Hurr will do the same very soon. DYOR, my initial target price 19p, I will wait to see this before making any decision whether to reduce my stake in Hurr

BG group taken over by Shell and from the same team Smith coming from...exciting time ahead
"Smith has been part of Hurricane since December 2019, and her most recent executive role was at oil & gas firm BG Group as vice president for Exploration & Growth in Europe from 2013 to 2016, before its takeover by Royal Dutch Shell PLC."

Karogeon also appointed their top gun with 50+ years experience who worked for Shell? They wont let go this co so cheaply, I remember they subscribed at 30p when Hurr raised £500m cash!

If we take their lowest value 54p and apply 40% on oil price taking $36 as base , hurri sp should be in the the the range of 32p to £1.20! I apply another 40% on 32p, my initial target price 19p!

Oil price is more likely to settle above $40, we should see hurricane to fly soon like Tullow and Pmo. I made similar statement when pmo was 13p and Tullow was 11p, I was topping up at that time ... let’s see if this time I get it wrong on hurr

Current MCAp is around £185m, at some point Hur raised cash £500m before producing any oil, now it is producing with massive reserve. Can we expect it goes above £500m mcap If so SP should be within 27p to 35p range. If oil price goes above $45, very soon we will see Hurr jump!

This statements provide some insight of the potential; if NHS signed up to use the test, huge revenue on the pipe line.

The antibody tests, which utilise the Quotient MosaiQ™ system and MosaiQ COVID-19 Antibody Microarray, offer best in class COVID-19 antibody testing performance and will require a full blood draw.
hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals. Samples will be tested in the Company's London laboratory with results returned within 48 hours.

This statements provide some insight of the potential; if NHS signed up to use the test, huge revenue on the pipe line.

The antibody tests, which utilise the Quotient MosaiQ™ system and MosaiQ COVID-19 Antibody Microarray, offer best in class COVID-19 antibody testing performance and will require a full blood draw.
hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals. Samples will be tested in the Company's London laboratory with results returned within 48 hours.

comments from

https://www.valuethemarkets.com/2020/05/18/open-orphan-share-price-spikes-as-covid-19-home-testing-stocks-rocket-orph/
"No other company in the world has a portfolio like Open Orphan. There are better-known companies, of course. But this company has advantages that no-one can reverse engineer. It is a world leader in human challenge studies and has Europe’s only 24-bed quarantine unit with a virology lab on-site.

Covid-19 aside, Open Orphan has major money-making deals already confirmed. It announced a £3.5 million contract signed earlier this month and a £3.2 million challenge study deal confirmed in March. It is also moving into Phase 3 clinical trials for the elusive and ground-breaking universal flu vaccine."

Don’t understand why price is still below 2p? Such a good news came today and has so much potential For waste water JV with MWG! Market seem not recognising any of this

I hope UK follow the same ....